In their study, 15 IgG4-RD patients received rituximab for 3-4 months, with dramatic clinical improvement, accompanied by a greater than 50% reduction in circulating CD4+ CTLs numbers and tissue fibrosis improved. This evidence concerns the gene CD4 and immunoglobulin G4-related sclerosing disease.